SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Elvis Presley — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElvis Presley
Date of birth1935-01-08
IdentifiersMRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417
Document date1974-08-07
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-week review on buprenorphine, before a Las Vegas engagement. [S]

History of Present Illness

Mr. Presley returns three weeks after starting buprenorphine. Withdrawal settled on the first day, and he has taken 16 mg every morning since, with mild cravings in the evenings after rehearsals and no other opioid. He had weekly phone contact and two counseling sessions. He has taken diazepam 10 mg four times daily and no alprazolam. He used CPAP on 82% of nights, for an average of 6.1 hours, and is less sleepy in the afternoons (Epworth 9). His home blood pressure has averaged 128/82 on amlodipine with valsartan, without ankle swelling or dizziness. His bowels open every one to two days, so he has stopped the senna. He is anxious about the three-week Las Vegas engagement starting in twelve days. He had to leave for a rehearsal before giving a urine sample. [S]

ElementDetail
Buprenorphine16 mg daily for three weeks; mild evening cravings; no other opioid
Diazepam40 mg a day; no alprazolam
CPAP82% of nights, 6.1 hours average; Epworth 9
Home blood pressureAverage 128/82
BowelsEvery one to two days; senna stopped
MoodPHQ-9 6; GAD-7 8

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy better
CardiovascularNegativeNo ankle swelling, dizziness or palpitations
GastrointestinalNegativeBowels regular; no nausea
PsychiatricPositiveAnxious about the engagement; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route1974-07-10 to 1974-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route1974-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route1974-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route1974-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route1974-07-10 to 1974-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route1974-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route1974-07-17 to 1974-08-07completedS
Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a timeOne tablet three times daily with the 2 mg tablets as scheduledOral route1974-08-07activeS
Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)Per the written taper scheduleOral route1974-08-07 to 1974-10-28completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route1974-07-17activeS
Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly2.5 mg once weeklySubcutaneous route1974-08-07 to 1974-09-23completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1974-08-07Body height183cmS
1974-08-07Body weight108.2kgS
1974-08-07Body mass index (BMI) [Ratio]32.3kg/m2S
1974-08-07Systolic blood pressure128mm[Hg]S
1974-08-07Diastolic blood pressure82mm[Hg]S
1974-08-07Heart rate76/minS
1974-08-07Respiratory rate14/minS
1974-08-07Body temperature36.7CelS
1974-08-07Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1974-08-07Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1974-08-07Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
1974-08-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M94mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1974-08-07Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1974-08-07Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S

Physical Exam

Vital signs recorded on 1974-08-07; see the Vital Signs section. [S]

SystemFinding
GeneralCalm and alert; blood pressure 128/82, pulse 76; weight 108.2 kg
EyesPupils 3 mm, equal and reactive
NeurologicalNo tremor or sedation

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, withdrawal symptoms, cravings and other opioid useEvery visit; weekly contact in the first monthCompleted today16 mg daily; no withdrawal after the first day; mild evening cravings; weekly calls done
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions
LaboratoryUrine drug test, including buprenorphine metabolite and fentanylAt the start of treatment, then about monthly while doses are changingDeferredNot collected: he left for a rehearsal before giving a sample. No harm is evident: the monitoring program shows only this clinic's prescriptions and he reports no other use. Corrective action: sample to be collected at the start of the next visit
Medication safetyNaloxone on hand and people taught to use itEvery visitCompleted todayAt home and in the tour bag
Medication safetyDiazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper paceEvery two to four weeks during the taperCompleted todayFirst step today, 40 to 36 mg a day (10%); no withdrawal symptoms
SurveySuicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan reviewed; firearms and medicines locked
SurveyMood (PHQ-9) and anxiety (GAD-7)At baseline, four to six weeks after a change in treatment, then at each reviewCompleted todayPHQ-9 6 (item 9 scored 0); GAD-7 8
ExaminationOffice and home blood pressure (target below 130/80)Every visitCompleted todayOffice 128/82; home average 128/82
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerTwo to four weeks after starting, then every six monthsCompleted todayPotassium 4.4, creatinine 1.04 three weeks after starting valsartan
ExaminationWeight and BMIEvery visitCompleted today108.2 kg, BMI 32.3
Medication safetyTirzepatide tolerance: nausea, vomiting, constipation, abdominal painAt each dose stepCompleted todayBaseline before the first dose: no nausea; bowels every one to two days
SurveyCPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)Within the first 30 to 90 days, then at each reviewCompleted today82% of nights, 6.1 hours; Epworth 9
Self-managementBowel frequency, straining and alarm featuresEvery visitCompleted todayEvery one to two days; senna stopped
ExaminationGlaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-upEvery visit; ophthalmology every three to six months while recently controlledCompleted todayDrops nightly; no eye symptoms; no new drug that affects eye pressure
Self-managementTouring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagementBefore each engagement or tourCompleted todayWritten plan for the Las Vegas engagement: one pharmacy, weekly video visits, travel CPAP, naloxone, no taper step while away

Goal progress:

Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022); Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Preventive visit next week. Weekly video visits during the engagement. Ten-week review after he returns. Next scheduled visit 1974-08-14: periodic adult preventive visit. [S]